Once daily tacrolimus

Astellas has launched Advagraf (tacrolimus), indicated for the prophylaxis of transplant rejection in kidney or liver allograft recipients and treatment of allograft rejection resistant to other immunosuppressants.

Advagraf is available as 0.5mg, 1mg and 5mg sustained-release capsules in a pack size of  28 capsules.

Further information: Astellas 01784 419615.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...